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Introduction: Malignant melanoma of the anal canal is a rare and aggressive disease, which 
early diagnosis is diffi cult. Its presentation with no specifi c symptoms leads to a late diag-
nosis at an advanced stage. The prognosis of anorectal malignant melanoma is poor and 
frequently related to distant metastasis and absence of response of chemoradiotherapy. 
Surgery remains the mainstay of therapy; otherwise, the best approach is controversial. 
Considering no survival benefi ts for APR, wide local excision should be considered as the 
treatment of choice. 
Methods: This report collects nine cases of anorectal melanoma treated at our division from 
1977 to 2006, as well as a review of the literature. 
Results: There were eight females and one male, of medium age 69 years (range: 41-85 
years). Most frequent presentation was bleeding. Wide Local Excision (WLE) was performed 
in seven of them. Mean survival was 24 months, and six of them died on account of meta-
static disease. 
Conclusion: Anorectal melanoma remains challenging. Efforts should be taken to early diag-
nosis, and wide local excision with negative margins is the preferred treatment. Abdomi-
noperineal resection (APR) is a reasonable option for bulky tumors or when the sphincter 
is invaded.
© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. 
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Melanoma anal: tumor raro, mas catastrófi co
Introdução: O melanoma maligno do canal anal é uma doença rara e agressiva, em que 
o diagnóstico precoce se torna difícil. Apresenta-se sem sintomas específi cos, levando ao 
diagnóstico tardio e em fase avançada. O prognóstico é ruim e frequentemente relacionado 
a metástases a distância, bem como à ausência de resposta à rádio e à quimioterapia. A 
cirurgia permanece como terapia de escolha, no entanto a melhor abordagem ainda é con-
troversa. Considerando não haver benefício na sobrevida da amputação abdômino-aerineal 
do aeto (AAPR), a excisão local ampla deve ser considerada o tratamento de escolha. 
Métodos: São nove casos de melanoma anorretal tratados no serviço de coloproctologia do 
Hospital Naval Marcílio Dias (HNMD) de 1977 a 2006. 
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Resultados: Foram diagnosticados oito mulheres e um homem, com média de idade de 69 
anos (41 - 85). A queixa mais frequente foi o sangramento anal. A excisão local ampla foi 
realizada em sete pacientes. A sobrevida média foi de 24 meses. 
Conclusão: O melanoma anorretal continua desafiante. Todos os esforços devem ser feitos 
para o diagnóstico precoce, tornando assim possível realizar a excisão local com margens 
negativas. A AAPR ainda é uma opção factível para tumores avançados ou quando o esfínc-
ter anal está comprometido.
© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. 
Introduction
Anal malignant melanoma is a rare and aggressive disease with 
no specific clinical symptoms and a poor outcome. It is often 
diagnosed at an advanced stage, presenting with hematoge-
nous metastasis. The anorectal region is the most common site 
for development of primary melanoma within the alimentary 
tract. The majority of the lesions arises from the dentate line of 
the anal canal and tends to spread submucosally.
Historically, anal melanoma was treated with abdomino-
perineal resection (APR), but recently some studies demon-
strated no difference of the survival rates comparing to wide 
local excision (WLE). It appears that the only benefit of radical 
surgery is to obtain clear margins in tumor that are particularly 
bulky or invading the sphincter, and here APR should be con-
sidered. So, WLE offers the advantage of avoiding a permanent 
colostomy and is the preferred treatment when negative mar-
gins can be achieved.1-4
Methods
The data of nine patients with anorectal melanoma were col-
lected and retrospectively analyzed. From 1977 to 2006 we 
had a total of nine cases, including one male and eight fe-
males. Patients complaint, tumor characteristics, type of sur-
gery, distant metastasis and overall survival were analyzed.
Due to the small number of patients, statistics analysis 
was not carried out.
Results
There were one male and eight females, of median age of 69 
(41-85) years. Most frequent complaint was rectal bleeding. 
Two patients had amelanotic melanomas. Among nine pa-
tients, none presented with distant metastasis when the time 
of diagnostic. Six were Caucasian. 
Seven patients underwent WLE, and one patient whose bi-
opsy revealed melanoma refused any further treatment. This 
patient returned two years later with a bulky bleeding tumor, 
and a palliative sigmoidostomy was performed combined 
with embolization due to severe bleeding. One patient, at the 
time of diagnosis, presented as frozen pelvis, and had not 
enough time to a surgical approach. The median overall sur-
vival was 24 months. Among patients who underwent WLE 
we missed the follow up of one patient, one patient presented 
a stroke and died five years after the procedure, and one pa-
tient is still alive (Figs. 1-6) (Table 1).
Fig. 2 – In clock hour: Dark pigmentation arising in anal 
verge extending to polypoid lesion in distal rectum (arrows). 
Wide local excision performed preserving the esfincter 
muscle. Melanotic pigment in the cytoplasm of neoplasic 
cells (case two).
Fig. 1 – In clock hour: Nodular lesion with yellow pigmentation 
at the top (arrow). Dark pigmentation on the basis of the 
nodular tumoration. Intense cellular pleomorphism and 
melanotic pigment in the cytoplasm (case one).
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Discussion
Anorectal malignant melanoma is a rare mucosal disease with 
a particularly aggressive biology compared with cutaneous 
melanoma of equal stage, accounting for approximately 1-4% of 
anorectal malignancies,2,5 but it is the third most common site 
after skin and eye and represents 0.6-1.6% of all melanomas.6,7
The majority of patients are Caucasian, with the highest 
incidence during sixth and seventh decade. There is a slight 
female preponderance. The anorectal melanoma arises from 
melanocytes present in the transitional zone of the surgical 
anal canal and tends to spread submucosally.8,9 Related to its 
no specific symptoms, most of them, presenting with bleed-
ing, prolapsed mass and anorectal pain, almost 60% of patients 
have already disseminated disease at initial diagnosis. Melano-
mas are commonly mistaken for hemorrhoidal disease, and the 
final diagnosis can be confirmed by positive excisional biopsy.1,2 
The lesion is not pigmented in about 30% of cases and may re-
semble a villous carcinoma, and carries a worse prognosis by its 
invasive nature.2,7,9
Immunohistochemical studies should always be done for 
establishing the diagnosis of melanoma. It is mostly positive 
for protein S-100 with a reported rate of 100%, melanoma anti-
gen HMB-45 and vimentin.8,10 Others tests, as endoluminal ul-
trasound and computed tomography, should be performed to 
address the extension and presence of metastatic disease as its 
Fig. 3 – In clock hour: Typical dark nodular lesion in anal 
margin with black pigmentation (arrows). Hystopathologic 
findings suitable of malignant melanoma (case four). Fig. 5 – In clock hour: Fungiform dark mass in distal 
rectum. After neoadjuvant radiotherapy, wide local 
excision with loop ileostomy. Brain methastasis one month 
after surgery. Hystopathologic findings show the lesion 
beginning at anal canal and extending to distal rectum 
(case seven).
Fig. 6 – In clock hour: Nodular lesion with dark pigmentation 
at the basis in anal verge (arrows). Local excision with 
sphincter preservation and marsupialization of the surgical 
incision. Complete healing at 180 days (case eight).
Fig. 4 – In clock hour: Vegetant and invasive lesion 
emerging from anal margin to pelvis, compromising rectal 
wall. Due to massive bleeding, it was performed arterial 
occlusion with coil (arrows). Late view after palliative 
radiotherapy (case six).
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diagnosis. The computed tomography can reveals intraluminal 
masses in the distal rectum, with perirectal infiltration and of-
ten enlarged lymph nodes. Endorectal ultrasound is helpful in 
the evaluation of the tumor thickness and its nodal status.2,8
Various factors, including duration of symptoms, inguinal 
lymph node involvement, tumor stage, the presence of amela-
notic melanoma on histology, tumor necrosis, perineural inva-
sion and tumor thickness, have been suggested to be negative 
prognostic factors. However, female sex has been suggested to 
be a positive prognostic factor for patients with cutaneous mel-
anoma, and with an improved survival after radical resection 
for regional stage of anal melanoma. This reason is unclear.8,9,11
The optimal treatment remains controversial, and surgery is 
based on two operative options: wide local excision (WLE) and 
abdominoperineal resection (APR). In the past, APR was advo-
cated for the nonmetastatic disease, but as the prognosis was 
poor regardless of surgical approach, the goal of the surgical 
procedure should be based on obtaining negative margins and 
maintaining sphincter function. Most studies shows APR to pro-
vide a better local control, but no clear improvement in survival, 
and further consideration must be given to quality of life issues 
when making decisions between these two options.2,5,8,9,12,13,15
Tumor thickness is a strong predictor factor for the risk 
of local recurrence and is used to plan therapeutic proce-
dures. Tumor thickness below 1mm can be performed by local 
sphincter-saving excision with a 1cm safety margin. Tumor 
thickness between 1-4 cm should be excised by sphincter-
saving excision and 2 cm safety margin, and tumor with 
thickness above 4 cm or with the involvement of sphincter 
should be treated with APR.8,9,11,13,14,18
Stoidis et al. hypothesized that systemic dissemination is 
an early event in tumorigenesis, and by the time the lesion is 
clinically apparent micrometastases are well established. Me-
tastases occur via lymphatic and hematogenous routes. Lym-
phatic spread to mesenteric nodes is more common than to 
inguinal nodes, while lungs, liver and bones are the most fre-
quent sites of distant metastases.8
Prophylactic lymph node resection has no value, and the 
therapeutic lymph node resection should be performed only 
in the presence of positive inguinal nodes. Sentinel lymph 
node mapping (SLNM) has influenced the extension of surgi-
cal resection and seems to be helpful in preventing understat-
ing patients, who are pathologically node-positive but clini-
cally node-negative and can allow early beneficial completion 
lymphadenectomy.5
The role of adjuvant therapy remains unknown. The re-
sponse of anorectal melanoma to radio and/or chemotherapy 
continues to be poor. No systemic therapy regimen for meta-
static anal melanoma is considered standard of care. Treat-
ment is based on drugs developed for advanced cutaneous 
melanoma, although the clinical, biologic, and molecular 
seems to be different.8 Kim et al. used a combination of temo-
zolomide, cisplatin and liposomal doxorubicin  for metastatic 
anal melanoma with encouraging results.4,17
Regardless of surgical approach, melanoma remains a 
highly lethal malignancy with overall 5-years survival rate 
less than 20%. The median survival is 34 months for patients 
with local disease and 10 months for those with metastatic 
disease.8,9
The early diagnosis is the key to improved survival rate for 
patients with anal melanoma, due to the fact that the stage 
of the disease is the most important determinant in anorec-
tal melanoma. A standard approach has not been established 
because of the limited number of patients of all anal mela-
noma reports. Further studies of the molecular mechanisms 
and tumor progression are needed to develop new treatment 
paradigms and improve survival.
Conclusion
Considering that anal melanoma is an aggressive tumor often 
diagnosed in advanced stages, a wide local excision should be 
considered as a therapeutic approach, despite controversial. 
Table 1 – Cases of anal melanoma.
CASES Year Age Gender Local Complaint Tumor 
appearance
Surgery Adjuvant 
therapy
Metastasis or 
recurrence 
(months)
Survival
1 1977 71 Female Anal Bleeding Hemorrhoidal 
thrombosis
Local excision Imuno +  
QT
Liver (24m) 70m
2 1977 69 Male Anorectal Bleeding Anal pigmented 
nodule
Local excision QT Rectum (6m) 14m
3 1993 58 Female Anorectal Anal 
discharge
Rectal ulcerated 
mass
Local excision QT + 
interferon
Lung (18m) 23m
4 1995 85 Female Anal Bleeding Anal pigmented 
nodule
Local excision No Groin (2m) 29m
5 1996 71 Female Anorectal Bleeding Rectal polyp Local excision No Rectum 
lymphnode (8m)
12m
6 1996 42 Female Anorectal Bleeding Anal polyp Sigmoidostomy + 
embolization
No Liver (35m) 40m
7 2004 41 Female Anorectal Bleeding Rectal pigmented 
nodule
Local excision + 
ileostomy
RT Brain (1m) 8m
8 2006 81 Female Anal Nodule Anal pigmented 
nodule
Local excision No No alive
9 2006 58 Female Anorectal Bleeding Rectal pigmented 
nodule and 
ulcerated mass
No No Frozen pelvis 1m
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There´s no significant impact in general survival with APR. So, 
WLE has its benefits in quality of life.13,16 
Conflicts of interest
The authors declare no conflicts of interest.
R E F E R E N C E S
1. Zhou HT, Zhou ZX, Zhang HZ, Bi JJ, Zhao P. Wide local excision 
could be considered as the initial treatment of primary 
anorectal malignant melanoma. Chin Med J (Engl). 2010 
Mar;123(5):585-8.
2. Trzcinski R, Kujawski R, Mik M, Sygut A, Dziki L, Dziki 
A. Malignant melanoma of the anorectum-a rare entity. 
Langenbecks Arch Surg. 2010 Jan 12. 
3. Khaled A, Hammami H, Fazaa B, Kourda N, Kamoun MR, 
Ben Jilany S, Zoghlami A. Primary amelanotic anorectal 
melanoma: an uncommon neoplasia with poor prognosis. 
Pathologica. 2009 Jun;101(3):126-9.
4. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton 
O, Camacho LH,  et al. Biochemotherapy in patients with 
metastatic anorectal mucosal melanoma. Cancer 2004, 
100:1478-1483.
5. Iddings DM, Fleisig AJ, Chen SL, Faries MB, Morton DL. 
Practice patterns and outcomes for anorectal melanoma 
in the USA, reviewing three decades of treatment: is more 
extensive surgical resection beneficial in all patients? Ann 
Surg Oncol 2010;17:40-44.
6. Nivatvongs S. Perianal and analcanal neoplasms. In: Gordon 
PH, Nivatvongs S, eds. Colon, Rectum and Anus. 3rd ed. New 
York: Informa Healthcare; 2007:369-390.
7. Garrett K, Kalady MF. Anal neoplasms. Surg Clin North Am 
2010;90:147-161, Table of Contents.
8. Stoidis CN, Spyropoulos BG, Misiakos EP, Fountzilas CK, 
Paraskeva PP, Fotiadis CI. Diffuse anorectal melanoma: review 
of the current diagnostic and treatment aspects based on a 
case report. World J Surg Oncol. 2009 Aug 11;7:64.
9. Sayari S, Moussi A, Bel Haj Salah R, Gherib SB, Haouet K, 
Zaouche A. Primary anorectal melanoma: a case report. Tunis 
Med. 2010 Jun;88(6):430-2.
10. Seya T, Tanaka N, Shinji S, Shinji E, Yokoi K, Horiba K, et 
al.2007. A case of rectal malignant melanoma showing 
immunohistochemial variability in a tumor. J Nippon Med 
Sch 74:377–381.
11. Kiran RP, Rottoli M, Pokala N, Fazio VW. Long-term outcomes 
after local excision and radical surgery for anal melanoma: 
data from a population database. Dis Colon Rectum. 2010 
Apr;53(4):402-8.
12. Bullard KM, Tuttle TM, Rothenberger DA, et al. Surgical 
therapy for anorectal melanoma. Journal of the American 
College of Surgeons2003;196:206-211. 
13. Thibault C, Sagar P, Nivatvongs S, Ilstrup DM, Wolff BG. 
Anorectal melanoma — an incurable disease? Dis Colon 
Rectum 1997;40:661-668.
14. Weyandt GH, Eggert AO, Houf M, Raulf F, Brocker EB, Becker 
JC. Anorectal melanoma: surgical management guidelines 
according to tumour thickness. Br J Cancer 2003;89:2019-2022.
15. Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal 
resection as surgical therapy for anorectal melanoma. Ann 
Surg2006;244:1012-1017.
16. Martínez-Hernández-Magro P, Villanueva-Sáenz E, Chávez-
Colunga L. Anal malignant melanoma. Case report 
and literature review. Rev Gastroenterol Mex. 2009 Jan-
Mar;74(1):39-44. 
17. Hay A, Liong J, Kumar D, Glees J. A striking response of 
anorectal melanoma to radiotherapy (locoregional disease 
confined to perineum and anal canal). Ann R Coll Surg Engl. 
2010 Jan;92(1):W10-2.
18. Nilsson PJ, Ragnarsson-Olding BK. Importance of clear 
resection margins in anorectal malignant melanoma. Br J 
Surg. 2010 Jan;97(1):98-103.
